MODEL SPOTLIGHT | C1498-Luc-mCherry: A Syngeneic Acute Myeloid Leukemia (AML) Model
Acute myeloid leukemia (AML) is the most common hematologic malignancy in adults with a 5-year survival rate of around 25% following diagnosis. Around 50% of patients who receive standard high-dose chemotherapy relapse after remission. This has created an impetus to explore novel immune-based therapies to combat heterogeneity of the disease.
We continue its efforts to expand characterization of the C1498-Luc-mCherry model for immuno-oncology applications. In our current spotlight we present data on the response to cyclophosphamide and immune checkpoint blockade. Download the PDF by filling out the form on this page.